TY  - GEN
AU  - Hellemans,R
AU  - Hazzan,M
AU  - Durand,D
AU  - Mourad,G
AU  - Lang,P
AU  - Kessler,M
AU  - Charpentier,B
AU  - Touchard,G
AU  - Berthoux,F
AU  - Merville,P
AU  - Ouali,N
AU  - Squifflet,J-P
AU  - Bayle,F
AU  - Wissing,K M
AU  - Noël,C
AU  - Abramowicz,D
TI  - Daclizumab Versus Rabbit Antithymocyte Globulin in High-Risk Renal Transplants: Five-Year Follow-up of a Randomized Study
SN  - 1600-6143
PY  - 2016///0628
KW  - Adult
KW  - Animals
KW  - Antibodies, Monoclonal, Humanized
KW  - therapeutic use
KW  - Antilymphocyte Serum
KW  - Daclizumab
KW  - Female
KW  - Follow-Up Studies
KW  - Glomerular Filtration Rate
KW  - Graft Rejection
KW  - prevention & control
KW  - Graft Survival
KW  - drug effects
KW  - Humans
KW  - Immunoglobulin G
KW  - Immunosuppressive Agents
KW  - Kidney Failure, Chronic
KW  - surgery
KW  - Kidney Function Tests
KW  - Kidney Transplantation
KW  - Male
KW  - Middle Aged
KW  - Postoperative Complications
KW  - Prognosis
KW  - Prospective Studies
KW  - Rabbits
KW  - Risk Factors
N1  - Publication Type: Comparative Study; Journal Article; Observational Study; Randomized Controlled Trial
UR  - https://doi.org/10.1111/ajt.13191
ER  -